Vela Technologies (GB:VELA) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vela Technologies, an early-stage tech investment firm, has announced their stake in Conduit Pharmaceuticals Inc. following Conduit’s entry into an exclusive licensing agreement with AstraZeneca for pioneering treatments. Vela’s investment is currently valued at approximately $170,000, representing 0.46% of Conduit, which plans to initiate Phase II clinical trials for potential first-in-class treatments for autoimmune disorders and idiopathic male infertility.
For further insights into GB:VELA stock, check out TipRanks’ Stock Analysis page.